Brokerage firm Citigroup Maintains its rating on Boston Scientific Corporation(NYSE:BSX). In a research note issued to the investors, the brokerage major Raises the price-target to $28.00 per share. The shares have been rated Buy. The rating by Citigroup was issued on Aug 3, 2016.
In a different note, On Jul 29, 2016, JP Morgan said it Maintains its rating on Boston Scientific Corporation. In the research note, the firm Raises the price-target to $24.00 per share. The shares have been rated ‘Overweight’ by the firm. On Jul 29, 2016, Jefferies said it Maintains its rating on Boston Scientific Corporation. In the research note, the firm Raises the price-target to $21.00 per share. The shares have been rated ‘Hold’ by the firm. Guggenheim Securities said it Initiates Coverage on Boston Scientific Corporation, according to a research note issued on Jun 9, 2016. The shares have been rated ‘Buy’ by the firm. On May 23, 2016, BTIG Research said it Downgrades its rating on Boston Scientific Corporation. The shares have been rated ‘Neutral’ by the firm.
Boston Scientific Corporation (BSX) made into the market gainers list on Fridays trading session with the shares advancing 0.13% or 0.03 points. Due to strong positive momentum, the stock ended at $23.89, which is also near the day’s high of $23.89. The stock began the session at $23.86 and the volume stood at 42,58,606 shares. The 52-week high of the shares is $24.79 and the 52 week low is $14.1801. The company has a current market capitalization of $32,508 M and it has 1,36,07,43,300 shares in outstanding.
Boston Scientific Corporation(BSX) last announced its earnings results on Jul 28, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $2.13B. Analysts had an estimated revenue of $2.05B. Earnings per share were $0.27. Analysts had estimated an EPS of $0.27.
Several Insider Transactions has been reported to the SEC. On Aug 2, 2016, Michael F Mahoney (President & CEO) sold 44,400 shares at $24.44 per share price.Also, On Aug 2, 2016, Timothy A. Pratt (EVP, GC & Chief Admin Officer) sold 24,000 shares at $24.46 per share price.On Jul 20, 2016, David A Pierce (SVP and President, Endoscopy) sold 2,480 shares at $24.03 per share price, according to the Form-4 filing with the securities and exchange commission.
Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Womens Health and Neuromodulation.